Case Report A 40-year-old white man with recently diagnosed acute myeloid leukemia presented to our hospital. HIV-1 infection have been diagnosed earlier a lot more than 10 years, and the patient had been treated with HAART for the previous 4 years, where no illnesses associated with the acquired immunodeficiency syndrome were observed. At the time that severe myeloid leukemia was diagnosed, the patient’s CD4 T-cell count was 415 per cubic millimeter, and HIV-1 RNA had not been detectable . Preliminary treatment of the acute myeloid leukemia consisted of two programs of induction chemotherapy and one span of consolidation chemotherapy. During the first induction training course, severe hepatic toxic effects developed and renal failure occurred. Consequently, HAART was discontinued, leading to a viral rebound .All checks were repeated twice, and we by no means detected a false positive result in the 224 samples acquired either from patients with other illnesses or healthy settings. As shown in Figure 3C, the 2 2 samples from this patient, collected 117 days aside, had been both positive for PrPSc, with similar features. However, the sample acquired later throughout the clinical disease seemed to have a bigger quantity of PrPSc, because it required one much less PMCA round for detection .